John B. Payne - 05 Jun 2024 Form 4 Insider Report for Zivo Bioscience, Inc. (ZIVO)

Role
President and CEO, Director
Signature
/s/ John B. Payne
Issuer symbol
ZIVO
Transactions as of
05 Jun 2024
Net transactions value
$0
Form type
4
Filing time
06 Jun 2024, 18:25:29 UTC
Previous filing
05 Apr 2023
Next filing
16 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -1,902 -100% 0 05 Jun 2024 Common Stock 1,902 $26.88 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -32,000 -100% 0 05 Jun 2024 Common Stock 32,000 $33.00 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -31,836 -100% 0 05 Jun 2024 Common Stock 31,836 $17.16 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Award +167,180 167,180 05 Jun 2024 Common Stock 167,180 $7.96 Direct F3, F4
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Award $0 +50,251 $0.000000 50,251 05 Jun 2024 Common Stock 50,251 $7.96 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023.
F2 The canceled options were fully vested.
F3 The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96.
F4 The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant.